Skip to main content
Monday, November 16, 2026Nov 16

FDA settles with drugmaker in fish-oil drug marketing case

FILE - This Oct. 14, 2015, file photo, shows the Food & Drug Administration campus in Silver Spring, Md. Amarin, the maker of a prescription fish-oil drug, said Tuesday, March 8, 2016, it has reached a legal settlement with the FDA that will allow it to promote unapproved uses of its drug for lowering fat levels. An FDA spokeswoman could not immediately comment. (AP Photo/Andrew Harnik, File)
FILE - This Oct. 14, 2015, file photo, shows the Food & Drug Administration campus in Silver Spring, Md. Amarin, the maker of a prescription fish-oil drug, said Tuesday, March 8, 2016, it has reached a legal settlement with the FDA that will allow it to promote unapproved uses of its drug for lowering fat levels. An FDA spokeswoman could not immediately comment. (AP Photo/Andrew Harnik, File)

WASHINGTON (AP) – The maker of a prescription fish-oil drug says it has reached a legal settlement that will allow it to promote unapproved uses of its drug for lowering fat levels.

The closely watched case between Amarin and the Food and Drug Administration could strengthen the drug industry’s hand in the ongoing debate over promoting drugs for uses that have not been declared safe and effective by regulators.

But the FDA said Tuesday the settlement is “specific to this particular case and situation,” and did not mark a new legal precedent.

“The FDA is responsible for protecting the American public by helping to ensure medical products meet the rigorous legal standards for safety and effectiveness for their intended uses,” the agency said in a statement.

Still, pharmaceutical experts said companies would likely pursue more aggressive legal action against FDA, in light of the settlement.